The absence of mrp4 has no effect on the recruitment of neutrophils and eosinophils into the lung after LPS, cigarette smoke or allergen challenge
The multidrug resistance protein 4 (Mrp4) is an ATP-binding cassette transporter that is capable of exporting the second messenger cAMP from cells, a process that might regulate cAMP-mediated anti-inflammatory processes. However, using LPS- or cigarette smoke (CS)-inflammation models, we found that...
Gespeichert in:
Veröffentlicht in: | PloS one 2013-04, Vol.8 (4), p.e61193-e61193 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | e61193 |
---|---|
container_issue | 4 |
container_start_page | e61193 |
container_title | PloS one |
container_volume | 8 |
creator | Schymeinsky, Jürgen Mayer, Hannah Tomsic, Christopher Tilp, Cornelia Schuetz, John D Cui, Yunhai Wollin, Lutz Gantner, Florian Erb, Klaus J |
description | The multidrug resistance protein 4 (Mrp4) is an ATP-binding cassette transporter that is capable of exporting the second messenger cAMP from cells, a process that might regulate cAMP-mediated anti-inflammatory processes. However, using LPS- or cigarette smoke (CS)-inflammation models, we found that neutrophil numbers in the bronchoalveolar lavage fluid (BALF) were similar in Mrp4(-/-) and Mrp4(+/+) mice treated with LPS or CS. Similarly, neutrophil numbers were not reduced in the BALF of LPS-challenged wt mice after treatment with 10 or 30 mg/kg of the Mrp1/4 inhibitor MK571. The absence of Mrp4 also had no impact on the influx of eosinophils or IL-4 and IL-5 levels in the BALF after OVA airway challenge in mice sensitized with OVA/alum. LPS-induced cytokine release in whole blood ex vivo was also not affected by the absence of Mrp4. These data clearly suggest that Mrp4 deficiency alone is not sufficient to reduce inflammatory processes in vivo. We hypothesized that in combination with PDE4 inhibitors, used at suboptimal concentrations, the anti-inflammatory effect would be more pronounced. However, LPS-induced neutrophil recruitment into the lung was no different between Mrp4(-/-) and Mrp4(+/+) mice treated with 3 mg/kg Roflumilast. Finally, the single and combined administration of 10 and 30 mg/kg MK571 and the specific breast cancer resistance protein (BCRP) inhibitor KO143 showed no reduction of LPS-induced TNFα release into the BALF compared to vehicle treated control animals. Similarly, LPS-induced TNFα release in murine whole blood of Mrp4(+/+) or Mrp4(-/-) mice was not reduced by KO143 (1, 10 µM). Thus, BCRP seems not to be able to compensate for the absence or inhibition of Mrp4 in the used models. Taken together, our data suggest that Mrp4 is not essential for the recruitment of neutrophils into the lung after LPS or CS exposure or of eosinophils after allergen exposure. |
doi_str_mv | 10.1371/journal.pone.0061193 |
format | Article |
fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1335054091</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A478172311</galeid><doaj_id>oai_doaj_org_article_e2e06dc047eb4f51a34e631a7c869e56</doaj_id><sourcerecordid>A478172311</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-2816730576a5d4d98ac9f31a30836e48d4b05ceb7b5a96212c4b1935e6cc6cb63</originalsourceid><addsrcrecordid>eNqNk29r1TAUxosobk6_gWhAEAXvNWnStH0jjOGfwYWJm74NaXraZqbJNUlFv4af2HTrxr2yF1Jo0-T3POfkJCfLnhK8JrQkby_d5K00662zsMaYE1LTe9lheucrnmN6f2d8kD0K4RLjglacP8wOcsoJrXB1mP25GADJJoBVgFyHRr9laJABWYeg60BF5CyKCfKg_KTjCDbOoIUpercdtAlI2haBC9ou_9pGd6Uxk-2R7CJ4tPl8_gYp3UsPMQIKo_ueAnokjQHfg0VqmIe2h8fZg06aAE-W71H29cP7i5NPq83Zx9OT481K8TqPq7wivKS4KLksWtbWlVR1R4mkuKIcWNWyBhcKmrIpZM1zkivWpIIUwJXiquH0KHt-7bs1LoilnEEQSgtcMFyTRJxeE62Tl2Lr9Sj9b-GkFlcTzvdC-qiVAQE5YN4qzEpoWFekNBjwlE2pKl5DMUd7t0SbmhFalcropdkz3V-xehC9-ykop3lxZfBqMfDuxwQhilEHBcZIC26a82bpDlS0ZAl98Q969-4WqpdpA9p2LsVVs6k4ZmVFypySmVrfQaWnhVGrdPc6neb3BK_3BImJ8Cv2cgpBnJ5_-X_27Ns--3KHHUCaOARnpqidDfsguwaVdyF46G6LTLCYW-emGmJuHbG0TpI92z2gW9FNr9C_lkEUFg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1335054091</pqid></control><display><type>article</type><title>The absence of mrp4 has no effect on the recruitment of neutrophils and eosinophils into the lung after LPS, cigarette smoke or allergen challenge</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Public Library of Science (PLoS) Journals Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Schymeinsky, Jürgen ; Mayer, Hannah ; Tomsic, Christopher ; Tilp, Cornelia ; Schuetz, John D ; Cui, Yunhai ; Wollin, Lutz ; Gantner, Florian ; Erb, Klaus J</creator><contributor>Ryffel, Bernhard</contributor><creatorcontrib>Schymeinsky, Jürgen ; Mayer, Hannah ; Tomsic, Christopher ; Tilp, Cornelia ; Schuetz, John D ; Cui, Yunhai ; Wollin, Lutz ; Gantner, Florian ; Erb, Klaus J ; Ryffel, Bernhard</creatorcontrib><description>The multidrug resistance protein 4 (Mrp4) is an ATP-binding cassette transporter that is capable of exporting the second messenger cAMP from cells, a process that might regulate cAMP-mediated anti-inflammatory processes. However, using LPS- or cigarette smoke (CS)-inflammation models, we found that neutrophil numbers in the bronchoalveolar lavage fluid (BALF) were similar in Mrp4(-/-) and Mrp4(+/+) mice treated with LPS or CS. Similarly, neutrophil numbers were not reduced in the BALF of LPS-challenged wt mice after treatment with 10 or 30 mg/kg of the Mrp1/4 inhibitor MK571. The absence of Mrp4 also had no impact on the influx of eosinophils or IL-4 and IL-5 levels in the BALF after OVA airway challenge in mice sensitized with OVA/alum. LPS-induced cytokine release in whole blood ex vivo was also not affected by the absence of Mrp4. These data clearly suggest that Mrp4 deficiency alone is not sufficient to reduce inflammatory processes in vivo. We hypothesized that in combination with PDE4 inhibitors, used at suboptimal concentrations, the anti-inflammatory effect would be more pronounced. However, LPS-induced neutrophil recruitment into the lung was no different between Mrp4(-/-) and Mrp4(+/+) mice treated with 3 mg/kg Roflumilast. Finally, the single and combined administration of 10 and 30 mg/kg MK571 and the specific breast cancer resistance protein (BCRP) inhibitor KO143 showed no reduction of LPS-induced TNFα release into the BALF compared to vehicle treated control animals. Similarly, LPS-induced TNFα release in murine whole blood of Mrp4(+/+) or Mrp4(-/-) mice was not reduced by KO143 (1, 10 µM). Thus, BCRP seems not to be able to compensate for the absence or inhibition of Mrp4 in the used models. Taken together, our data suggest that Mrp4 is not essential for the recruitment of neutrophils into the lung after LPS or CS exposure or of eosinophils after allergen exposure.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0061193</identifier><identifier>PMID: 23613808</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Adenosine ; Adenosine - analogs & derivatives ; Adenosine - pharmacology ; Allergens ; Allergens - immunology ; Allergy ; Alum ; Aluminum sulfate ; Alveoli ; Analysis ; Animal models ; Animals ; Asthma ; Asthma - immunology ; Asthma - metabolism ; ATP Binding Cassette Transporter, Sub-Family G, Member 2 ; ATP-Binding Cassette Transporters - metabolism ; Biology ; Blood ; Breast cancer ; Bronchoalveolar lavage ; Bronchoalveolar Lavage Fluid ; Bronchus ; Chronic obstructive pulmonary disease ; Cigarette smoke ; Cyclic adenosine monophosphate ; Cyclic AMP ; Cyclic AMP - blood ; Cytokines ; Cytokines - metabolism ; Diketopiperazines ; Eosinophils ; Eosinophils - drug effects ; Eosinophils - immunology ; Exposure ; Heterocyclic Compounds, 4 or More Rings ; Inflammation ; Inhibitors ; Interleukin 4 ; Interleukin 5 ; Kinases ; Leukocytes (eosinophilic) ; Leukocytes (neutrophilic) ; Lipopolysaccharides ; Lipopolysaccharides - pharmacology ; Lung - drug effects ; Lung - immunology ; Lung - metabolism ; Lungs ; Medicine ; Mice ; Microbial drug resistance ; Multidrug resistance ; Multidrug Resistance-Associated Proteins - deficiency ; Multidrug Resistance-Associated Proteins - metabolism ; Neutrophils ; Neutrophils - drug effects ; Neutrophils - immunology ; Ovalbumin - immunology ; Phosphodiesterase ; Phosphodiesterase 4 Inhibitors - pharmacology ; Plasma ; Propionates - pharmacology ; Proteins ; Pulmonary Disease, Chronic Obstructive - immunology ; Pulmonary Disease, Chronic Obstructive - metabolism ; Quinolines - pharmacology ; Recruitment ; Respiratory diseases ; Respiratory tract ; Rodents ; Rolipram - pharmacology ; Smoke ; Smoking ; Smoking - adverse effects ; Smooth muscle ; Th2 Cells - drug effects ; Th2 Cells - immunology ; Time Factors ; Transporter ; Tumor necrosis factor-TNF ; Tumor necrosis factor-α</subject><ispartof>PloS one, 2013-04, Vol.8 (4), p.e61193-e61193</ispartof><rights>COPYRIGHT 2013 Public Library of Science</rights><rights>2013 Schymeinsky et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2013 Schymeinsky et al 2013 Schymeinsky et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-2816730576a5d4d98ac9f31a30836e48d4b05ceb7b5a96212c4b1935e6cc6cb63</citedby><cites>FETCH-LOGICAL-c692t-2816730576a5d4d98ac9f31a30836e48d4b05ceb7b5a96212c4b1935e6cc6cb63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3632556/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3632556/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,865,886,2103,2929,23871,27929,27930,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23613808$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Ryffel, Bernhard</contributor><creatorcontrib>Schymeinsky, Jürgen</creatorcontrib><creatorcontrib>Mayer, Hannah</creatorcontrib><creatorcontrib>Tomsic, Christopher</creatorcontrib><creatorcontrib>Tilp, Cornelia</creatorcontrib><creatorcontrib>Schuetz, John D</creatorcontrib><creatorcontrib>Cui, Yunhai</creatorcontrib><creatorcontrib>Wollin, Lutz</creatorcontrib><creatorcontrib>Gantner, Florian</creatorcontrib><creatorcontrib>Erb, Klaus J</creatorcontrib><title>The absence of mrp4 has no effect on the recruitment of neutrophils and eosinophils into the lung after LPS, cigarette smoke or allergen challenge</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>The multidrug resistance protein 4 (Mrp4) is an ATP-binding cassette transporter that is capable of exporting the second messenger cAMP from cells, a process that might regulate cAMP-mediated anti-inflammatory processes. However, using LPS- or cigarette smoke (CS)-inflammation models, we found that neutrophil numbers in the bronchoalveolar lavage fluid (BALF) were similar in Mrp4(-/-) and Mrp4(+/+) mice treated with LPS or CS. Similarly, neutrophil numbers were not reduced in the BALF of LPS-challenged wt mice after treatment with 10 or 30 mg/kg of the Mrp1/4 inhibitor MK571. The absence of Mrp4 also had no impact on the influx of eosinophils or IL-4 and IL-5 levels in the BALF after OVA airway challenge in mice sensitized with OVA/alum. LPS-induced cytokine release in whole blood ex vivo was also not affected by the absence of Mrp4. These data clearly suggest that Mrp4 deficiency alone is not sufficient to reduce inflammatory processes in vivo. We hypothesized that in combination with PDE4 inhibitors, used at suboptimal concentrations, the anti-inflammatory effect would be more pronounced. However, LPS-induced neutrophil recruitment into the lung was no different between Mrp4(-/-) and Mrp4(+/+) mice treated with 3 mg/kg Roflumilast. Finally, the single and combined administration of 10 and 30 mg/kg MK571 and the specific breast cancer resistance protein (BCRP) inhibitor KO143 showed no reduction of LPS-induced TNFα release into the BALF compared to vehicle treated control animals. Similarly, LPS-induced TNFα release in murine whole blood of Mrp4(+/+) or Mrp4(-/-) mice was not reduced by KO143 (1, 10 µM). Thus, BCRP seems not to be able to compensate for the absence or inhibition of Mrp4 in the used models. Taken together, our data suggest that Mrp4 is not essential for the recruitment of neutrophils into the lung after LPS or CS exposure or of eosinophils after allergen exposure.</description><subject>Adenosine</subject><subject>Adenosine - analogs & derivatives</subject><subject>Adenosine - pharmacology</subject><subject>Allergens</subject><subject>Allergens - immunology</subject><subject>Allergy</subject><subject>Alum</subject><subject>Aluminum sulfate</subject><subject>Alveoli</subject><subject>Analysis</subject><subject>Animal models</subject><subject>Animals</subject><subject>Asthma</subject><subject>Asthma - immunology</subject><subject>Asthma - metabolism</subject><subject>ATP Binding Cassette Transporter, Sub-Family G, Member 2</subject><subject>ATP-Binding Cassette Transporters - metabolism</subject><subject>Biology</subject><subject>Blood</subject><subject>Breast cancer</subject><subject>Bronchoalveolar lavage</subject><subject>Bronchoalveolar Lavage Fluid</subject><subject>Bronchus</subject><subject>Chronic obstructive pulmonary disease</subject><subject>Cigarette smoke</subject><subject>Cyclic adenosine monophosphate</subject><subject>Cyclic AMP</subject><subject>Cyclic AMP - blood</subject><subject>Cytokines</subject><subject>Cytokines - metabolism</subject><subject>Diketopiperazines</subject><subject>Eosinophils</subject><subject>Eosinophils - drug effects</subject><subject>Eosinophils - immunology</subject><subject>Exposure</subject><subject>Heterocyclic Compounds, 4 or More Rings</subject><subject>Inflammation</subject><subject>Inhibitors</subject><subject>Interleukin 4</subject><subject>Interleukin 5</subject><subject>Kinases</subject><subject>Leukocytes (eosinophilic)</subject><subject>Leukocytes (neutrophilic)</subject><subject>Lipopolysaccharides</subject><subject>Lipopolysaccharides - pharmacology</subject><subject>Lung - drug effects</subject><subject>Lung - immunology</subject><subject>Lung - metabolism</subject><subject>Lungs</subject><subject>Medicine</subject><subject>Mice</subject><subject>Microbial drug resistance</subject><subject>Multidrug resistance</subject><subject>Multidrug Resistance-Associated Proteins - deficiency</subject><subject>Multidrug Resistance-Associated Proteins - metabolism</subject><subject>Neutrophils</subject><subject>Neutrophils - drug effects</subject><subject>Neutrophils - immunology</subject><subject>Ovalbumin - immunology</subject><subject>Phosphodiesterase</subject><subject>Phosphodiesterase 4 Inhibitors - pharmacology</subject><subject>Plasma</subject><subject>Propionates - pharmacology</subject><subject>Proteins</subject><subject>Pulmonary Disease, Chronic Obstructive - immunology</subject><subject>Pulmonary Disease, Chronic Obstructive - metabolism</subject><subject>Quinolines - pharmacology</subject><subject>Recruitment</subject><subject>Respiratory diseases</subject><subject>Respiratory tract</subject><subject>Rodents</subject><subject>Rolipram - pharmacology</subject><subject>Smoke</subject><subject>Smoking</subject><subject>Smoking - adverse effects</subject><subject>Smooth muscle</subject><subject>Th2 Cells - drug effects</subject><subject>Th2 Cells - immunology</subject><subject>Time Factors</subject><subject>Transporter</subject><subject>Tumor necrosis factor-TNF</subject><subject>Tumor necrosis factor-α</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNk29r1TAUxosobk6_gWhAEAXvNWnStH0jjOGfwYWJm74NaXraZqbJNUlFv4af2HTrxr2yF1Jo0-T3POfkJCfLnhK8JrQkby_d5K00662zsMaYE1LTe9lheucrnmN6f2d8kD0K4RLjglacP8wOcsoJrXB1mP25GADJJoBVgFyHRr9laJABWYeg60BF5CyKCfKg_KTjCDbOoIUpercdtAlI2haBC9ou_9pGd6Uxk-2R7CJ4tPl8_gYp3UsPMQIKo_ueAnokjQHfg0VqmIe2h8fZg06aAE-W71H29cP7i5NPq83Zx9OT481K8TqPq7wivKS4KLksWtbWlVR1R4mkuKIcWNWyBhcKmrIpZM1zkivWpIIUwJXiquH0KHt-7bs1LoilnEEQSgtcMFyTRJxeE62Tl2Lr9Sj9b-GkFlcTzvdC-qiVAQE5YN4qzEpoWFekNBjwlE2pKl5DMUd7t0SbmhFalcropdkz3V-xehC9-ykop3lxZfBqMfDuxwQhilEHBcZIC26a82bpDlS0ZAl98Q969-4WqpdpA9p2LsVVs6k4ZmVFypySmVrfQaWnhVGrdPc6neb3BK_3BImJ8Cv2cgpBnJ5_-X_27Ns--3KHHUCaOARnpqidDfsguwaVdyF46G6LTLCYW-emGmJuHbG0TpI92z2gW9FNr9C_lkEUFg</recordid><startdate>20130422</startdate><enddate>20130422</enddate><creator>Schymeinsky, Jürgen</creator><creator>Mayer, Hannah</creator><creator>Tomsic, Christopher</creator><creator>Tilp, Cornelia</creator><creator>Schuetz, John D</creator><creator>Cui, Yunhai</creator><creator>Wollin, Lutz</creator><creator>Gantner, Florian</creator><creator>Erb, Klaus J</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20130422</creationdate><title>The absence of mrp4 has no effect on the recruitment of neutrophils and eosinophils into the lung after LPS, cigarette smoke or allergen challenge</title><author>Schymeinsky, Jürgen ; Mayer, Hannah ; Tomsic, Christopher ; Tilp, Cornelia ; Schuetz, John D ; Cui, Yunhai ; Wollin, Lutz ; Gantner, Florian ; Erb, Klaus J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-2816730576a5d4d98ac9f31a30836e48d4b05ceb7b5a96212c4b1935e6cc6cb63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adenosine</topic><topic>Adenosine - analogs & derivatives</topic><topic>Adenosine - pharmacology</topic><topic>Allergens</topic><topic>Allergens - immunology</topic><topic>Allergy</topic><topic>Alum</topic><topic>Aluminum sulfate</topic><topic>Alveoli</topic><topic>Analysis</topic><topic>Animal models</topic><topic>Animals</topic><topic>Asthma</topic><topic>Asthma - immunology</topic><topic>Asthma - metabolism</topic><topic>ATP Binding Cassette Transporter, Sub-Family G, Member 2</topic><topic>ATP-Binding Cassette Transporters - metabolism</topic><topic>Biology</topic><topic>Blood</topic><topic>Breast cancer</topic><topic>Bronchoalveolar lavage</topic><topic>Bronchoalveolar Lavage Fluid</topic><topic>Bronchus</topic><topic>Chronic obstructive pulmonary disease</topic><topic>Cigarette smoke</topic><topic>Cyclic adenosine monophosphate</topic><topic>Cyclic AMP</topic><topic>Cyclic AMP - blood</topic><topic>Cytokines</topic><topic>Cytokines - metabolism</topic><topic>Diketopiperazines</topic><topic>Eosinophils</topic><topic>Eosinophils - drug effects</topic><topic>Eosinophils - immunology</topic><topic>Exposure</topic><topic>Heterocyclic Compounds, 4 or More Rings</topic><topic>Inflammation</topic><topic>Inhibitors</topic><topic>Interleukin 4</topic><topic>Interleukin 5</topic><topic>Kinases</topic><topic>Leukocytes (eosinophilic)</topic><topic>Leukocytes (neutrophilic)</topic><topic>Lipopolysaccharides</topic><topic>Lipopolysaccharides - pharmacology</topic><topic>Lung - drug effects</topic><topic>Lung - immunology</topic><topic>Lung - metabolism</topic><topic>Lungs</topic><topic>Medicine</topic><topic>Mice</topic><topic>Microbial drug resistance</topic><topic>Multidrug resistance</topic><topic>Multidrug Resistance-Associated Proteins - deficiency</topic><topic>Multidrug Resistance-Associated Proteins - metabolism</topic><topic>Neutrophils</topic><topic>Neutrophils - drug effects</topic><topic>Neutrophils - immunology</topic><topic>Ovalbumin - immunology</topic><topic>Phosphodiesterase</topic><topic>Phosphodiesterase 4 Inhibitors - pharmacology</topic><topic>Plasma</topic><topic>Propionates - pharmacology</topic><topic>Proteins</topic><topic>Pulmonary Disease, Chronic Obstructive - immunology</topic><topic>Pulmonary Disease, Chronic Obstructive - metabolism</topic><topic>Quinolines - pharmacology</topic><topic>Recruitment</topic><topic>Respiratory diseases</topic><topic>Respiratory tract</topic><topic>Rodents</topic><topic>Rolipram - pharmacology</topic><topic>Smoke</topic><topic>Smoking</topic><topic>Smoking - adverse effects</topic><topic>Smooth muscle</topic><topic>Th2 Cells - drug effects</topic><topic>Th2 Cells - immunology</topic><topic>Time Factors</topic><topic>Transporter</topic><topic>Tumor necrosis factor-TNF</topic><topic>Tumor necrosis factor-α</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schymeinsky, Jürgen</creatorcontrib><creatorcontrib>Mayer, Hannah</creatorcontrib><creatorcontrib>Tomsic, Christopher</creatorcontrib><creatorcontrib>Tilp, Cornelia</creatorcontrib><creatorcontrib>Schuetz, John D</creatorcontrib><creatorcontrib>Cui, Yunhai</creatorcontrib><creatorcontrib>Wollin, Lutz</creatorcontrib><creatorcontrib>Gantner, Florian</creatorcontrib><creatorcontrib>Erb, Klaus J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schymeinsky, Jürgen</au><au>Mayer, Hannah</au><au>Tomsic, Christopher</au><au>Tilp, Cornelia</au><au>Schuetz, John D</au><au>Cui, Yunhai</au><au>Wollin, Lutz</au><au>Gantner, Florian</au><au>Erb, Klaus J</au><au>Ryffel, Bernhard</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The absence of mrp4 has no effect on the recruitment of neutrophils and eosinophils into the lung after LPS, cigarette smoke or allergen challenge</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2013-04-22</date><risdate>2013</risdate><volume>8</volume><issue>4</issue><spage>e61193</spage><epage>e61193</epage><pages>e61193-e61193</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>The multidrug resistance protein 4 (Mrp4) is an ATP-binding cassette transporter that is capable of exporting the second messenger cAMP from cells, a process that might regulate cAMP-mediated anti-inflammatory processes. However, using LPS- or cigarette smoke (CS)-inflammation models, we found that neutrophil numbers in the bronchoalveolar lavage fluid (BALF) were similar in Mrp4(-/-) and Mrp4(+/+) mice treated with LPS or CS. Similarly, neutrophil numbers were not reduced in the BALF of LPS-challenged wt mice after treatment with 10 or 30 mg/kg of the Mrp1/4 inhibitor MK571. The absence of Mrp4 also had no impact on the influx of eosinophils or IL-4 and IL-5 levels in the BALF after OVA airway challenge in mice sensitized with OVA/alum. LPS-induced cytokine release in whole blood ex vivo was also not affected by the absence of Mrp4. These data clearly suggest that Mrp4 deficiency alone is not sufficient to reduce inflammatory processes in vivo. We hypothesized that in combination with PDE4 inhibitors, used at suboptimal concentrations, the anti-inflammatory effect would be more pronounced. However, LPS-induced neutrophil recruitment into the lung was no different between Mrp4(-/-) and Mrp4(+/+) mice treated with 3 mg/kg Roflumilast. Finally, the single and combined administration of 10 and 30 mg/kg MK571 and the specific breast cancer resistance protein (BCRP) inhibitor KO143 showed no reduction of LPS-induced TNFα release into the BALF compared to vehicle treated control animals. Similarly, LPS-induced TNFα release in murine whole blood of Mrp4(+/+) or Mrp4(-/-) mice was not reduced by KO143 (1, 10 µM). Thus, BCRP seems not to be able to compensate for the absence or inhibition of Mrp4 in the used models. Taken together, our data suggest that Mrp4 is not essential for the recruitment of neutrophils into the lung after LPS or CS exposure or of eosinophils after allergen exposure.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>23613808</pmid><doi>10.1371/journal.pone.0061193</doi><tpages>e61193</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1932-6203 |
ispartof | PloS one, 2013-04, Vol.8 (4), p.e61193-e61193 |
issn | 1932-6203 1932-6203 |
language | eng |
recordid | cdi_plos_journals_1335054091 |
source | MEDLINE; DOAJ Directory of Open Access Journals; Public Library of Science (PLoS) Journals Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry |
subjects | Adenosine Adenosine - analogs & derivatives Adenosine - pharmacology Allergens Allergens - immunology Allergy Alum Aluminum sulfate Alveoli Analysis Animal models Animals Asthma Asthma - immunology Asthma - metabolism ATP Binding Cassette Transporter, Sub-Family G, Member 2 ATP-Binding Cassette Transporters - metabolism Biology Blood Breast cancer Bronchoalveolar lavage Bronchoalveolar Lavage Fluid Bronchus Chronic obstructive pulmonary disease Cigarette smoke Cyclic adenosine monophosphate Cyclic AMP Cyclic AMP - blood Cytokines Cytokines - metabolism Diketopiperazines Eosinophils Eosinophils - drug effects Eosinophils - immunology Exposure Heterocyclic Compounds, 4 or More Rings Inflammation Inhibitors Interleukin 4 Interleukin 5 Kinases Leukocytes (eosinophilic) Leukocytes (neutrophilic) Lipopolysaccharides Lipopolysaccharides - pharmacology Lung - drug effects Lung - immunology Lung - metabolism Lungs Medicine Mice Microbial drug resistance Multidrug resistance Multidrug Resistance-Associated Proteins - deficiency Multidrug Resistance-Associated Proteins - metabolism Neutrophils Neutrophils - drug effects Neutrophils - immunology Ovalbumin - immunology Phosphodiesterase Phosphodiesterase 4 Inhibitors - pharmacology Plasma Propionates - pharmacology Proteins Pulmonary Disease, Chronic Obstructive - immunology Pulmonary Disease, Chronic Obstructive - metabolism Quinolines - pharmacology Recruitment Respiratory diseases Respiratory tract Rodents Rolipram - pharmacology Smoke Smoking Smoking - adverse effects Smooth muscle Th2 Cells - drug effects Th2 Cells - immunology Time Factors Transporter Tumor necrosis factor-TNF Tumor necrosis factor-α |
title | The absence of mrp4 has no effect on the recruitment of neutrophils and eosinophils into the lung after LPS, cigarette smoke or allergen challenge |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T02%3A56%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20absence%20of%20mrp4%20has%20no%20effect%20on%20the%20recruitment%20of%20neutrophils%20and%20eosinophils%20into%20the%20lung%20after%20LPS,%20cigarette%20smoke%20or%20allergen%20challenge&rft.jtitle=PloS%20one&rft.au=Schymeinsky,%20J%C3%BCrgen&rft.date=2013-04-22&rft.volume=8&rft.issue=4&rft.spage=e61193&rft.epage=e61193&rft.pages=e61193-e61193&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0061193&rft_dat=%3Cgale_plos_%3EA478172311%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1335054091&rft_id=info:pmid/23613808&rft_galeid=A478172311&rft_doaj_id=oai_doaj_org_article_e2e06dc047eb4f51a34e631a7c869e56&rfr_iscdi=true |